Asymptomatic COVID-19: disease tolerance with efficient anti-viral immunity against SARS-CoV-2

无症状 COVID-19:对 SARS-CoV-2 具有有效抗病毒免疫力的疾病耐受性

阅读:8
作者:Yi-Hao Chan, Siew-Wai Fong, Chek-Meng Poh, Guillaume Carissimo, Nicholas Kim-Wah Yeo, Siti Naqiah Amrun, Yun Shan Goh, Jackwee Lim, Weili Xu, Rhonda Sin-Ling Chee, Anthony Torres-Ruesta, Cheryl Yi-Pin Lee, Matthew Zirui Tay, Zi Wei Chang, Wen-Hsin Lee, Bei Wang, Seow-Yen Tan, Shirin Kalimuddin, Barn

Abstract

The immune responses and mechanisms limiting symptom progression in asymptomatic cases of SARS-CoV-2 infection remain unclear. We comprehensively characterized transcriptomic profiles, cytokine responses, neutralization capacity of antibodies, and cellular immune phenotypes of asymptomatic patients with acute SARS-CoV-2 infection to identify potential protective mechanisms. Compared to symptomatic patients, asymptomatic patients had higher counts of mature neutrophils and lower proportion of CD169+ expressing monocytes in the peripheral blood. Systemic levels of pro-inflammatory cytokines were also lower in asymptomatic patients, accompanied by milder pro-inflammatory gene signatures. Mechanistically, a more robust systemic Th2 cell signature with a higher level of virus-specific Th17 cells and a weaker yet sufficient neutralizing antibody profile against SARS-CoV-2 was observed in asymptomatic patients. In addition, asymptomatic COVID-19 patients had higher systemic levels of growth factors that are associated with cellular repair. Together, the data suggest that asymptomatic patients mount less pro-inflammatory and more protective immune responses against SARS-CoV-2 indicative of disease tolerance. Insights from this study highlight key immune pathways that could serve as therapeutic targets to prevent disease progression in COVID-19.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。